Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Boosted by MetLife Investment Management LLC

MetLife Investment Management LLC lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 7.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 145,265 shares of the biopharmaceutical company's stock after purchasing an additional 10,538 shares during the quarter. MetLife Investment Management LLC owned about 0.11% of Halozyme Therapeutics worth $6,945,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. Smartleaf Asset Management LLC grew its position in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust raised its position in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Up 2.1 %

NASDAQ HALO traded up $1.24 on Friday, hitting $60.49. 992,970 shares of the stock traded hands, compared to its average volume of 1,435,271. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The stock has a 50-day moving average of $60.50 and a 200 day moving average of $55.09. Halozyme Therapeutics, Inc. has a twelve month low of $37.97 and a twelve month high of $66.00. The company has a market capitalization of $7.47 billion, a P/E ratio of 17.64, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. JPMorgan Chase & Co. boosted their price objective on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research note on Monday. HC Wainwright reiterated a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Benchmark reaffirmed a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $62.89.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now owns 38,611 shares of the company's stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock valued at $1,286,568 in the last three months. 2.90% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.